Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1974 3
1975 1
1976 1
1977 1
1978 4
1979 2
1980 2
1981 2
1982 1
1983 1
1984 1
1985 1
1990 1
1992 2
1993 4
1995 2
1996 2
1997 2
1998 2
2001 10
2002 3
2003 11
2004 3
2005 3
2006 1
2007 3
2008 3
2009 1
2010 2
2011 3
2012 3
2013 4
2014 10
2015 5
2016 3
2017 6
2018 3
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Results by year
Filters applied: . Clear all
Page 1
Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H, Perttilä R, Niininen W, Barker H, Ungureanu D. Karvonen H, et al. Among authors: Ungureanu D. Eur J Haematol. 2018 Oct;101(4):457-465. doi: 10.1111/ejh.13137. Epub 2018 Sep 5. Eur J Haematol. 2018. PMID: 29989208 Review.
Targeting ROR1 identifies new treatment strategies in hematological cancers.
Karvonen H, Niininen W, Murumägi A, Ungureanu D. Karvonen H, et al. Among authors: Ungureanu D. Biochem Soc Trans. 2017 Apr 15;45(2):457-464. doi: 10.1042/BST20160272. Biochem Soc Trans. 2017. PMID: 28408486 Review.
Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H, Perttilä R, Niininen W, Hautanen V, Barker H, Murumägi A, Heckman CA, Ungureanu D. Karvonen H, et al. Among authors: Ungureanu D. Oncogene. 2019 Apr;38(17):3288-3300. doi: 10.1038/s41388-018-0670-9. Epub 2019 Jan 10. Oncogene. 2019. PMID: 30631148
Immune therapies for malignant mesothelioma.
Antoniu SA, Dimofte G, Ungureanu D. Antoniu SA, et al. Among authors: Ungureanu D. Expert Rev Anticancer Ther. 2014 Aug;14(8):965-73. doi: 10.1586/14737140.2014.919859. Epub 2014 May 16. Expert Rev Anticancer Ther. 2014. PMID: 24833011 Review.
Interaction between ROR1 and MuSK activation complex in myogenic cells.
Karvonen H, Summala K, Niininen W, Barker HR, Ungureanu D. Karvonen H, et al. Among authors: Ungureanu D. FEBS Lett. 2018 Feb;592(3):434-445. doi: 10.1002/1873-3468.12966. Epub 2018 Jan 14. FEBS Lett. 2018. PMID: 29292499 Free article.
Vitamin D status in patients admitted in a clinic of endocrinology.
Găleanu C, Florescu A, Ungureanu MC, Grozavu I, Loghin A, Ungureanu D. Găleanu C, et al. Among authors: Ungureanu MC, Ungureanu D. Rev Med Chir Soc Med Nat Iasi. 2014 Apr-Jun;118(2):327-32. Rev Med Chir Soc Med Nat Iasi. 2014. PMID: 25076695
Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies.
Veskimäe K, Scaravilli M, Niininen W, Karvonen H, Jaatinen S, Nykter M, Visakorpi T, Mäenpää J, Ungureanu D, Staff S. Veskimäe K, et al. Among authors: Ungureanu D. Transl Oncol. 2018 Oct;11(5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. Epub 2018 Jul 26. Transl Oncol. 2018. PMID: 30056367 Free PMC article.
New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O, Ungureanu D, Niranjan Y, Hammaren H, Bandaranayake R, Hubbard SR. Silvennoinen O, et al. Among authors: Ungureanu D. Biochem Soc Trans. 2013 Aug;41(4):1002-7. doi: 10.1042/BST20130005. Biochem Soc Trans. 2013. PMID: 23863170 Review.
115 results
Jump to page
Feedback